Ivy Q. Tonnu-Mihara

Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease

Alexander T. Sandhu, Adam Furst, Fátima Elizondo Rodríguez, Neil M. Kalwani et autres

BACKGROUND: Systemic inflammation (SI), measured by high-sensitivity C-reactive protein (hsCRP), is common in both atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD). OBJECTIVES: The objectives of the study was to evaluate the association between SI and cardiovascular and economic outcomes among …

us (code pays fourni par la source)

Trends in post-discharge major adverse cardiovascular events following myocardial infarction: Insights from the veterans healthcare administration

Alexander T. Sandhu, Adam Furst, Fatima Rodriguez, Neil Kalwani et autres

us (code pays fourni par la source)

Abstract 4363122: Temporal Trends in Major Adverse Cardiovascular Events Following Hospitalization for Myocardial Infarction Between 2008-2022: Insights from the Veterans Affairs Healthcare System

Alexander T. Sandhu, Adam Furst, Fatima Rodriguez, Neil M. Kalwani et autres

Background: Over 800,000 individuals are hospitalized for a myocardial infarction (MI) annually in the United States. Temporal trends in post-discharge outcomes are uncertain. Question: Among Veterans who survive an MI hospitalization, how have post-discharge outcomes changed? Methods: Veterans who survived an MI …

us (code pays fourni par la source)

Abstract 4341999: Clinical Outcomes Among Individuals with Persistent Systemic Inflammation Following Myocardial Infarction: Insights from the Veterans Affairs Healthcare System

Alexander T. Sandhu, Adam Furst, Fátima Elizondo Rodríguez, Neil M. Kalwani et autres

Introduction: Acute myocardial infarction (MI) triggers acute inflammation. A subset of patients experience subsequent chronic systemic inflammation (SI) post-MI. Question: Among patients with a prior MI, is SI associated with a higher risk of major adverse cardiovascular (CV) events? Methods: We identified …

us (code pays fourni par la source)

Real-World Retrospective Study of Clinical and Economic Outcomes Among Patients with Locally Advanced or Metastatic Urothelial Carcinoma Treated with First-Line Systemic Anti-Cancer Therapies in the United States: Results from the IMPACT UC-III Study

Helen Moon, Chiemeka Ike, Christopher L. Crowe, Malvika Venkataraman et autres

This retrospective cohort study evaluated characteristics, treatment patterns, and clinical outcomes in adults with locally advanced/metastatic urothelial carcinoma (la/mUC) receiving first-line (1L) systemic treatment with or without avelumab 1L maintenance (1LM) between January 2020 and July 2023. The index date was the …

us, de (code pays fourni par la source)

A Real-world Evaluation of Longitudinal Healthcare Expenses in a Health System Registry of Type-2 Diabetes Mellitus and Cardiovascular Disease Enabled by the 21st Century Cures Act

Lovedeep Singh Dhingra, Aline F Pedroso, Arya Aminorroaya, JIGAR R. RAJPURA et autres

Introduction: Century Cures Act, which mandated reporting hospital-level service, we pursued a comprehensive evaluation of healthcare spending in a diverse cohort of individuals with T2D. Methods: We designed a pragmatic, observational cohort study of patients with T2D seeking regular care (≥ 1 …

us (code pays fourni par la source)

Abstract 4118451: A Real-world Evaluation of Longitudinal Healthcare Expenses in a Health System Registry of Type-2 Diabetes Mellitus and Cardiovascular Disease Enabled by the 21 st Century Cures Act

Lovedeep Singh Dhingra, Arya Aminorroaya, Aline Pedroso Camargos, JIGAR R. RAJPURA et autres

Background: An evaluation of the longitudinal burden of healthcare expenses in type-2 diabetes mellitus (T2DM) is limited to self-selected cohorts and claims-based or self-reported spending. Leveraging the 21 st Century Cures Act rule that made reporting hospital-level service prices mandatory, we demonstrate …

us (code pays fourni par la source)

Real-world (rw) treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line (1L) systemic tx and avelumab 1L maintenance (1LM): Results from the IMPACT UC-III study.

Helen Moon, Chiemeka Ike, Valerie A. Morris, Ruth Wangia Dixon et autres

390 Background: Avelumab 1LM is a standard of care for pts with mUC that has not progressed after 1L platinum-based chemotherapy (PBC). Immuno-oncology (IO) monotherapy is considered in pts with mUC who are ineligible to receive PBC. Recently approved 1L tx options …

us, de (code pays fourni par la source)

Evaluating the burden of illness of metabolic dysfunction–associated steatohepatitis in a large managed care population: The ETHEREAL Study

Michael Charlton, Ivy Q. Tonnu-Mihara, Chia‐Chen Teng, Ziqi Zhou et autres

BACKGROUND: Metabolic dysfunction-associated steatohepatitis (MASH; formerly nonalcoholic steatohepatitis) is the inflammatory form of metabolic dysfunction-associated steatotic liver disease (formerly nonalcoholic fatty liver disease). MASH is a progressive disease associated with increased risk for many hepatic and extra-hepatic complications such as cirrhosis, hepatocellular …

us, gb (code pays fourni par la source)

The clinical and economic burdens of metabolic dysfunction-associated steatohepatitis

Michael Charlton, Ivy Q. Tonnu-Mihara, Chia‐Chen Teng, Ziqi Zhou et autres

Aims This study aimed to assess and compare the health care resource utilization (HCRU) and medical cost of metabolic dysfunction-associated steatohepatitis (MASH) by disease severity based on Fibrosis-4 Index (FIB-4) score among US adults in a real-world setting.Materials and methods This observational …

us, it (code pays fourni par la source)

SA42 Innovative Methods for Integrating Social Determinants of Health Data with Administrative Claims to Facilitate Health Equity Research

Ivy Q. Tonnu-Mihara, C. Rojas-Lazic, Michelle Mack, Birhanu Eshete et autres

us (code pays fourni par la source)

Comparative Effectiveness of Roflumilast and Azithromycin for the Treatment of Chronic Obstructive Pulmonary Disease

Jenny Lam, Ivy Q. Tonnu-Mihara, Nicholas J. Kenyon, Brooks Kuhn

BACKGROUND: In chronic obstructive pulmonary disease (COPD) patients with exacerbations despite optimized bronchodilator therapy, roflumilast and chronic azithromycin are recommended options. Roflumilast is recommended in severe COPD patients with chronic bronchitis, whereas chronic azithromycin is more broadly indicated. The comparative effectiveness between …

us (code pays fourni par la source)